There was a lot of excitement when Tepezza became the first drug approved for the treatment of thyroid eye disease in January 2020. Then, COVID hit.
“Sort of terrible timing with regards to that,” Richard C. Allen, MD, PhD, FACS, said. “There was a lot of initial excitement, and then everybody’s clinic shut down.”
Despite this initial pandemic-spurred letdown, Tepezza (teprotumumab-trbw, Amgen) has changed the landscape of treatment in thyroid eye disease (TED).
“Thyroid eye disease has kind of been revamped as far as how we think about treatment for the disease,”